Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (69)	1/8/1999 1:54:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 3158

Well I guess OSIP agrees with the thesis of this thread, which is no surprise. The open question of course is whether the hunters agree. Note that this "shareholder rights" plan (it should of course be called a "management rights" plan) is probably not addressed to collaborators like Pfizer, which is already a substantial shareholder (they bought 1/2 million shares back in 1986) or like HMR (1 1/2 million shares). These purchase agreements typically contain "standstill" clauses that prevent the acquisition of more than a certain percentage ownership by the partner. Interesting to see what the H&Q conference next week brings. We should get some good news from the conference (as companies historically have hoarded some good news for it), and the sector is also due for some FDA approvals (LGND, DEPO, SEPR). The burning question is whether people are going to see good news as a selling opportunity or a buying one. Peer